Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer
Multi-target-directed ligands (MTDL) or Designed Multiple Ligands (DML) use a single chemical substance to affect several ligands or targets associated with a disease to boost efficacy or safety. In recent studies, many novel quinolones have adapted this strategy by targeting many cancer ligands, in...
Published in: | Current Trends in Biotechnology and Pharmacy |
---|---|
Main Authors: | , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | https://research.monash.edu/en/publications/20d48092-f90d-485a-ac4b-7cf279f1894d https://doi.org/10.5530/ctbp.2023.4s.84 https://researchmgt.monash.edu/ws/files/581419021/567114378_oa.pdf http://www.scopus.com/inward/record.url?scp=85179666969&partnerID=8YFLogxK |
id |
ftmonashunicris:oai:monash.edu:publications/20d48092-f90d-485a-ac4b-7cf279f1894d |
---|---|
record_format |
openpolar |
spelling |
ftmonashunicris:oai:monash.edu:publications/20d48092-f90d-485a-ac4b-7cf279f1894d 2024-10-20T14:08:20+00:00 Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer Azzman, Nursyuhada Gill, Muhammad Shoaib Ali Hassan, Sharifah Syed Ahemad, Nafees 2023-12-13 application/pdf https://research.monash.edu/en/publications/20d48092-f90d-485a-ac4b-7cf279f1894d https://doi.org/10.5530/ctbp.2023.4s.84 https://researchmgt.monash.edu/ws/files/581419021/567114378_oa.pdf http://www.scopus.com/inward/record.url?scp=85179666969&partnerID=8YFLogxK eng eng info:eu-repo/semantics/openAccess Azzman , N , Gill , M S A , Hassan , S S & Ahemad , N 2023 , ' Review : exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer ' , Current Trends in Biotechnology and Pharmacy , vol. 17 , no. 4A , pp. 8-14 . https://doi.org/10.5530/ctbp.2023.4s.84 anticancer DML hybrids quinolones topoisomerase inhibitor tyrosine kinases article 2023 ftmonashunicris https://doi.org/10.5530/ctbp.2023.4s.84 2024-10-07T14:30:26Z Multi-target-directed ligands (MTDL) or Designed Multiple Ligands (DML) use a single chemical substance to affect several ligands or targets associated with a disease to boost efficacy or safety. In recent studies, many novel quinolones have adapted this strategy by targeting many cancer ligands, including topoisomerase, tyrosine kinase, tubulin polymerisation, and formation of G-quadruplex. Moreover, the effectiveness of anticancer quinolones has been improved by the conjugation of compounds with metal complexes, such as ruthenium (III), boron, and copper (II). In the case of dual inhibitors, most of the substances target topoisomerases along with additional targets such as histone deacetylases, telomerase, microtubules, kinases, heat shock protein 90 (Hsp90), aldehyde dehydrogenase 1 (ALDH1) and proteasomes. Some of these hybrids, such as CX-5461, Q84441, and A-74441, have been shown to be effective against solid tumors with improved safety profiles. In this review, the current quinolone hybrids and DML strategy against a range of targets will be examined with the hope that the insights will aid in the development of novel quinolone derivatives for cancer treatment. Article in Journal/Newspaper DML Monash University Research Portal Current Trends in Biotechnology and Pharmacy 17 4A 8 14 |
institution |
Open Polar |
collection |
Monash University Research Portal |
op_collection_id |
ftmonashunicris |
language |
English |
topic |
anticancer DML hybrids quinolones topoisomerase inhibitor tyrosine kinases |
spellingShingle |
anticancer DML hybrids quinolones topoisomerase inhibitor tyrosine kinases Azzman, Nursyuhada Gill, Muhammad Shoaib Ali Hassan, Sharifah Syed Ahemad, Nafees Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer |
topic_facet |
anticancer DML hybrids quinolones topoisomerase inhibitor tyrosine kinases |
description |
Multi-target-directed ligands (MTDL) or Designed Multiple Ligands (DML) use a single chemical substance to affect several ligands or targets associated with a disease to boost efficacy or safety. In recent studies, many novel quinolones have adapted this strategy by targeting many cancer ligands, including topoisomerase, tyrosine kinase, tubulin polymerisation, and formation of G-quadruplex. Moreover, the effectiveness of anticancer quinolones has been improved by the conjugation of compounds with metal complexes, such as ruthenium (III), boron, and copper (II). In the case of dual inhibitors, most of the substances target topoisomerases along with additional targets such as histone deacetylases, telomerase, microtubules, kinases, heat shock protein 90 (Hsp90), aldehyde dehydrogenase 1 (ALDH1) and proteasomes. Some of these hybrids, such as CX-5461, Q84441, and A-74441, have been shown to be effective against solid tumors with improved safety profiles. In this review, the current quinolone hybrids and DML strategy against a range of targets will be examined with the hope that the insights will aid in the development of novel quinolone derivatives for cancer treatment. |
format |
Article in Journal/Newspaper |
author |
Azzman, Nursyuhada Gill, Muhammad Shoaib Ali Hassan, Sharifah Syed Ahemad, Nafees |
author_facet |
Azzman, Nursyuhada Gill, Muhammad Shoaib Ali Hassan, Sharifah Syed Ahemad, Nafees |
author_sort |
Azzman, Nursyuhada |
title |
Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer |
title_short |
Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer |
title_full |
Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer |
title_fullStr |
Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer |
title_full_unstemmed |
Review:exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer |
title_sort |
review:exploring the potential of designed multiple ligands (dml) strategy with quinolones as anticancer |
publishDate |
2023 |
url |
https://research.monash.edu/en/publications/20d48092-f90d-485a-ac4b-7cf279f1894d https://doi.org/10.5530/ctbp.2023.4s.84 https://researchmgt.monash.edu/ws/files/581419021/567114378_oa.pdf http://www.scopus.com/inward/record.url?scp=85179666969&partnerID=8YFLogxK |
genre |
DML |
genre_facet |
DML |
op_source |
Azzman , N , Gill , M S A , Hassan , S S & Ahemad , N 2023 , ' Review : exploring the potential of Designed Multiple Ligands (DML) strategy with quinolones as anticancer ' , Current Trends in Biotechnology and Pharmacy , vol. 17 , no. 4A , pp. 8-14 . https://doi.org/10.5530/ctbp.2023.4s.84 |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.5530/ctbp.2023.4s.84 |
container_title |
Current Trends in Biotechnology and Pharmacy |
container_volume |
17 |
container_issue |
4A |
container_start_page |
8 |
op_container_end_page |
14 |
_version_ |
1813447448603918336 |